Stephanie Heller1,2, Uwe Kölsch3, Thomas Magg4, Renate Krüger1, Andrea Scheuern5, Holm Schneider6, Anna Eichinger4, Volker Wahn1, Nadine Unterwalder3, Myriam Lorenz7, Klaus Schwarz7,8, Christian Meisel2,3, Ansgar Schulz5, Fabian Hauck4, Horst von Bernuth9,10,11. 1. Department of Pediatric Pulmonology, Immunology, and Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany. 2. Berlin-Brandenburg Center for Regenerative Therapies, Berlin, Germany. 3. Department of Immunology, Labor Berlin GmbH, Berlin, Germany. 4. Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital LMU, Munich, Germany. 5. Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany. 6. Center for Ectodermal Dysplasias and Department of Pediatrics, University Hospital Erlangen, Erlangen, Germany. 7. Institute for Transfusion Medicine, University of Ulm, Ulm, Germany. 8. Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Service, Ulm, Germany. 9. Department of Pediatric Pulmonology, Immunology, and Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Berlin, Germany. horst.von-bernuth@charite.de. 10. Berlin-Brandenburg Center for Regenerative Therapies, Berlin, Germany. horst.von-bernuth@charite.de. 11. Department of Immunology, Labor Berlin GmbH, Berlin, Germany. horst.von-bernuth@charite.de.
Abstract
PURPOSE: NEMO-deficient patients present with variable degrees of immunodeficiency. Accordingly, treatment ranges from antibiotic prophylaxis and/or IgG-substitution to allogenic hematopoietic stem cell transplantation (HSCT). The correct estimation of the immunodeficiency is essential to avoid over- as well as under-treatment. We compare the immunological phenotype of a NEMO-deficient patient with a newly-described splice site mutation that causes truncation of the NEMO zinc-finger (ZF) domain and a severe clinical course with the immunological phenotype of three NEMO-deficient patients with missense mutations and milder clinical courses and all previously published patients. METHODS: Lymphocyte subsets, proliferation, and intracellular NEMO-expression were assessed by FACS. NF-κB signal transduction was determined by measuring IκBα-degradation and the production of cytokines upon stimulation with TNF-α, IL-1β, and TLR-agonists in immortalized fibroblasts and whole blood, respectively. RESULTS: The patient with truncated ZF-domain of NEMO showed low levels of IgM and IgG, reduced class-switched memory B cells, almost complete skewing towards naïve CD45RA+ T cells, impaired T cell proliferation as well as cytokine production upon stimulation with TNF-α, IL-1β, and TLR-agonists. He suffered from severe infections (sepsis, pneumonia, osteomyelitis) during infancy. In contrast, three patients with missense mutations in IKBKG presented neither skewing of T cells towards naïvety nor impaired T cell proliferation. They are stable on prophylactic IgG-substitution or even off any prophylactic treatment. CONCLUSION: The loss of the ZF-domain and the impaired T cell proliferation accompanied by almost complete persistence of naïve T cells despite severe infections are suggestive for a profound immunodeficiency. Allogenic HSCT should be considered early for these patients before chronic sequelae occur.
PURPOSE:NEMO-deficientpatients present with variable degrees of immunodeficiency. Accordingly, treatment ranges from antibiotic prophylaxis and/or IgG-substitution to allogenic hematopoietic stem cell transplantation (HSCT). The correct estimation of the immunodeficiency is essential to avoid over- as well as under-treatment. We compare the immunological phenotype of a NEMO-deficientpatient with a newly-described splice site mutation that causes truncation of the NEMO zinc-finger (ZF) domain and a severe clinical course with the immunological phenotype of three NEMO-deficientpatients with missense mutations and milder clinical courses and all previously published patients. METHODS: Lymphocyte subsets, proliferation, and intracellular NEMO-expression were assessed by FACS. NF-κB signal transduction was determined by measuring IκBα-degradation and the production of cytokines upon stimulation with TNF-α, IL-1β, and TLR-agonists in immortalized fibroblasts and whole blood, respectively. RESULTS: The patient with truncated ZF-domain of NEMO showed low levels of IgM and IgG, reduced class-switched memory B cells, almost complete skewing towards naïve CD45RA+ T cells, impaired T cell proliferation as well as cytokine production upon stimulation with TNF-α, IL-1β, and TLR-agonists. He suffered from severe infections (sepsis, pneumonia, osteomyelitis) during infancy. In contrast, three patients with missense mutations in IKBKG presented neither skewing of T cells towards naïvety nor impaired T cell proliferation. They are stable on prophylactic IgG-substitution or even off any prophylactic treatment. CONCLUSION: The loss of the ZF-domain and the impaired T cell proliferation accompanied by almost complete persistence of naïve T cells despite severe infections are suggestive for a profound immunodeficiency. Allogenic HSCT should be considered early for these patients before chronic sequelae occur.
Entities:
Keywords:
CD45RA+ naïve T cells; NEMO deficiency; Primary immunodeficiency; T cell deficiency; immunological phenotype
Authors: Jana M Pachlopnik Schmid; Sonja A Junge; Johann Peter Hossle; E Marion Schneider; Eddy Roosnek; Reinhard A Seger; Tayfun Gungor Journal: Pediatrics Date: 2006-04-24 Impact factor: 7.124
Authors: Laurence E Cheng; Bittoo Kanwar; Haig Tcheurekdjian; James P Grenert; Mica Muskat; Melvin B Heyman; Joseph M McCune; Diane W Wara Journal: Clin Immunol Date: 2009-04-16 Impact factor: 3.969
Authors: Haifa H Jabara; Toshiro Ohsumi; Janet Chou; Michel J Massaad; Halli Benson; Andre Megarbane; Eliane Chouery; Raymond Mikhael; Oliver Gorka; Andreas Gewies; Pierre Portales; Toshinori Nakayama; Hiroyuki Hosokawa; Patrick Revy; Henry Herrod; Francoise Le Deist; Gerard Lefranc; Jürgen Ruland; Raif S Geha Journal: J Allergy Clin Immunol Date: 2013-05-31 Impact factor: 10.793
Authors: Geoffrey D E Cuvelier; Tamar S Rubin; Anne Junker; Roona Sinha; Alan M Rosenberg; Donna A Wall; Marlis L Schroeder Journal: Clin Immunol Date: 2018-10-31 Impact factor: 3.969
Authors: Frank J Ivins; Mark G Montgomery; Susan J M Smith; Aylin C Morris-Davies; Ian A Taylor; Katrin Rittinger Journal: Biochem J Date: 2009-06-26 Impact factor: 3.857
Authors: Henry Y Lu; Bradly M Bauman; Swadhinya Arjunaraja; Batsukh Dorjbal; Joshua D Milner; Andrew L Snow; Stuart E Turvey Journal: Front Immunol Date: 2018-09-19 Impact factor: 7.561